key: cord-0863230-uo1t0xnh
authors: Amoah, Albert G.B.; Quakyi, Isabella A.; Sagoe, Kwamena W.; Ayettey-Anie, Hannah N.G.; Ayettey-Adamafio, Mary N.B.; Ayettey Brew, Ruth N.A.; Newman-Nartey, Merley; Nartey, Nii Otu; Brightson, Kennedy T.C.; Kessie, Gladstone; Ayettey, Andrews S.; Konotey-Ahulu, Felix I.D.
title: RE: ORAL ANTISEPTICS AGAINST CORONAVIRUS: IN-VITRO AND CLINICAL EVIDENCE
date: 2021-09-03
journal: J Hosp Infect
DOI: 10.1016/j.jhin.2021.08.024
sha: b167cbc2272d93f1e442667b79e07706ea09b6d2
doc_id: 863230
cord_uid: uo1t0xnh

nan

PMCID: PMC8046704, the authors after a review of existing literature found sufficient in vitro but not in vivo evidence on the use of oral antiseptics including hydrogen peroxide (HP) to inactivate or eradicate SARS-CoV-2. 1 The need for use of oral antiseptics for the fight against COVID-19 cannot be over emphasized. Currently, it is uncertain how long neutralizing antibodies will last after vaccination, and there is uncertainty about the efficacy of the existing COVID-19 vaccines with the emergence of SARS-CoV-2 variants (ref). 2 3 Furthermore, even at the current level of global vaccinations estimated at 6.7 million doses per day, it has been projected that herd immunity will be achieved in approximately 4.6 years, if 70 to 85% of the population receive a two-dose vaccine. 4 We had earlier proposed the use of HP as mouthwash and nasal rinse to prevent SARS-CoV-2 infection thereby limiting transmission. 5 We share our observations of the impact of HP use on the occurrence of COVID-19 in two groups of healthcare workers (HCW); those using HP for oral and nasal rinse (HP-HCW) and those not using it (NHP-HCW), at a district-level hospital and at a private hospital where in-patients also were given HP as topical prophylaxis. This situational analysis involved gross data collection with permission from the institutions who had willingly introduced voluntary use of HP, and did not involve any direct contact with patients or HCW.

At the Emergency Department of the Shai OsuDoku District Hospital (SODH) in the Greater Accra Region in Ghana, eight nurses were using HP for mouthwash and gargle and for nasal lavage.

These nurses who are permanent and core staff at the Emergency Department adopted this prophylactic measure from May 2020 when they heard about the efficacy of HP against coronaviruses. They daily mouth-washed and gargled with 1% solution of HP and rinsed their nasal cavities with a lower concentration (0.5%). They and all other nurses at the hospital wore standard scrubs, gloves and boots, in addition to wearing face masks, and to frequent handwashing under running water and hand-sanitizing. Since they were the first to receive such patients and triage them before a diagnosis of COVID-19 was made, they adopted measures they felt could protect them. At the time these eight emergency staff nurses adopted prophylactic use of HP, (Table 1 ).

in November 2020, got infected again in January 2021, a period less than three months. Aside these, we found that in January 2021 when other staff at SODH began using HP, one person who used it in an office of 5 staff was the only one who did not contract the COVID-19. The remaining four had COVID-19 and were not using HP.

At the Mt. Olives Hospital where HP prophylaxis was introduced and involved 3,378 in-patients, only two staff had COVID-19 within 8 months (August 2020 to March 2021), compared with 17 staff infections between July 6 th and early August 2020 and before HP was introduced to both staff and in-patients. Within that same period July 6 th to early August 2020, five in-patients also had COVID-19 (Table 1) . It was also observed that two cases of COVID-19 occurred in staff using HP infrequently, and not in those not using HP at all in the period (Table 1) . As the results show, no cases of COVID-19 were recorded in the MO hospital among patients, HP-HCW and NHP-HCW with the novel introduction of HP prophylaxis for in-patients. We therefore believe that the daily use of HP was what protected the 3387 in-patients and 52 HP-HCW from COVID-19, by inactivating SARS-CoV-2 that may have attached to ACE2 cells within the buccal cavity and upper respiratory tract. It is also possible that the HP prophylaxis policy adopted by MO benefitted the 30 NHP-HCW. It is noteworthy to mention that a short-term inhibition of SARS-CoV-2 by HP has been shown in persistent nasopharyngeal carriers. 6 The need for prompt hospital based and community studies is emphasized, since post vaccination infections are occuring 7 and the delta variant is currently spreading. 8 J o u r n a l P r e -p r o o f

Oral antiseptics against coronavirus: in-vitro and clinical evidence

SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

From Vaccine Nationalism to Vaccine Equity -Finding a Path Forward

A Case for Hydrogen Peroxide Mouthwash and Gargle to Limit SARS-CoV-2 Infection

Short-term inhibition of SARS-CoV-2 by hydrogen peroxide in persistent nasopharyngeal carriers

Variants of concern are overrepresented among post-vaccination breakthrough infections of SARS-CoV-2 in Washington State

Covid-19: Cases of delta variant rise by 79%, but rate of growth slows